LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year. In a recent interview with Urology Times®, Kevin C. Zorn, MD, FRCSC, ...
Non-muscle invasive bladder cancer treatments have expanded beyond BCG, offering alternatives to radical cystectomy with flexible dosing and scheduling. Muscle-invasive bladder cancer management is ...
Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate cancer. The trial showed consistent benefits across clinical endpoints, ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 mg/m2 docetaxel regimen. Despite a higher cumulative docetaxel dose, the 50 ...
New guidelines emphasize evidence-based management of genitourinary injuries, involving multidisciplinary input from experts in urology, trauma surgery, and military medicine. Recommendations include ...
Pembrolizumab plus axitinib showed superior overall survival and progression-free survival compared to sunitinib in advanced clear cell renal cell carcinoma. The combination therapy demonstrated a ...
"We are not offering patients comprehensive management unless we consider hormone therapies," says Ashley G. Winter, MD. On July 17, 2025, a panel of experts convened by the FDA outlined the growing ...
Metabolic health, especially HbA1c levels, significantly influences sexual function in aging men more than age alone. Increases in HbA1c correlate with declines in sperm motility and erectile function ...
NCCN guideline-recommended treatments significantly reduce prostate cancer mortality compared to other causes, even in high-risk patients. The study involved 135,636 Swedish patients, with 46% ...
A notable finding was that 35% of these NMIBC patients exhibited ctDNA positivity. A notable finding was that 35% of these NMIBC patients exhibited ctDNA positivity, which was an unexpected and ...
The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback